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Abstract: Epizootic hemorrhagic disease virus (EHDV) is an arthropod-transmitted RNA virus and
the causative agent of epizootic hemorrhagic disease (EHD) in wild and domestic ruminants. In North
America, white-tailed deer (WTD) experience the highest EHD-related morbidity and mortality,
although clinical disease is reported in cattle during severe epizootics. No commercially licensed
EHDV vaccine is available in North America. The objective of this study was to develop and evaluate
a subunit vaccine candidate to control EHD in WTD. Recombinant VP2 (rVP2) outer capsid proteins
of EHDV serotypes 2 (EHDV-2) and 6 (EHDV-6) were produced in a baculovirus-expression system.
Mice and cattle vaccinated with EHDV-2 or EHDV-6 rVP2 produced homologous virus-neutralizing
antibodies. In an immunogenicity/efficacy study, captive-bred WTD received 2 doses of EHDV-2 rVP2
or sham vaccine, then were challenged with wild-type EHDV-2 at 30 d post vaccination. None of the
rVP2-vaccinated deer developed clinical disease, no viral RNA was detected in their blood or tissues
(liver, lung, spleen, kidney), and no EHDV-induced lesions were observed. Sham-vaccinated deer
developed clinical disease with viremia and typical EHD vascular lesions. Here, we demonstrate a
rVP2 subunit vaccine that can provide protective immunity from EHDV infection and which may
serve as an effective tool in preventing clinical EHD and reducing virus transmission.
Keywords: white-tailed deer; cattle; epizootic hemorrhagic disease virus; subunit vaccine
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1. Introduction
Epizootic hemorrhagic disease (EHD) is an arthropod-transmitted viral disease of wild and
domestic ruminants. The causative agent of EHD is epizootic hemorrhagic disease virus (EHDV; genus
Orbivirus, family Reoviridae), a non-enveloped dsRNA virus closely related to bluetongue virus (BTV) [1].
The geographic distribution of EHDV is broad and includes Africa, the Americas, Australia, Asia, and the
Mediterranean basin [2]. With a few exceptions, this distribution is related to the presence of its arthropod
vector, namely hematophagous biting midges of the genus Culicoides [3]. The numerous strains of EHDV
are categorized into seven serotypes: 1, 2, and 4-8 [4], with serotype 1, 2, and 6 viruses known to circulate
in North America [5]. Serotype 2 (EHDV-2) was first isolated in North America in 1962 in Alberta, Canada,
and has been the predominant serotype identified in EHD outbreaks in recent years in the United States
(U.S.) [6–8]. However, surveillance studies indicate that serotype 6 (EHDV-6), which was first detected in
the U.S. in 2006, likely has since become established throughout the country [9].
EHD has been documented in multiple cervid and bovid species, but primarily impacts North
American white-tailed deer (WTD; Odocoileus virginianus) [10]. EHD can occur as peracute, acute,
or chronic disease syndromes with considerable variation in presentation between geographic regions.
In the southern U.S., disease may be asymptomatic or mild as a result of prior exposure of susceptible
animals, whereas in more northern areas where exposure is sporadic, severe cases of EHD with
hemorrhagic manifestations and death occur more frequently [11]. However, the patterns of disease
are dynamic, and there is evidence that the frequency, severity, and geographic range of EHD has
increased in recent decades [8]. In susceptible wildlife populations, outbreak-related mortality rates
of up to 20% have been estimated [12]. In North America, EHD epizootics have also had substantial
effects on commercial deer farming—a rapidly growing industry that had an estimated $7.9 billion
total economic impact on the U.S. economy in 2015 [13]. There is evidence that farmed deer may
experience higher EHDV exposures than wild deer living in adjacent areas [14].
Clinical disease is typically less common in EHDV-infected cattle, with some notable exceptions.
In Asia, Ibaraki virus (IBAV), a strain of EHDV-2, sporadically causes Ibaraki disease—an acute febrile
disease which can resemble bluetongue [15]. Reports of bluetongue-like clinical disease in cattle
during recent EHDV outbreaks in North America, the Mediterranean Basin, and Reunion Island
have also raised concerns about an apparent increase in pathogenicity of additional virus strains in
cattle [5,16,17]. EHDV can produce oral lesions in cattle that can resemble those of transboundary
diseases such as foot-and-mouth disease, thus EHD-affected premises can be subject to foreign animal
disease investigation and animal movement restrictions.
Despite these impacts of EHDV infection on livestock production systems, no commercial EHDV
vaccines are currently licensed for use in North America; only inactivated autogenous vaccines have been
available [18]. In Japan, inactivated and live–attenuated (modified live) virus vaccines are available for
control of IBAV; however, these vaccines do not permit the differentiation between infected and vaccinated
animals (DIVA), which is necessary for some intervention strategies. Application of recombinant subunit
protein based-vaccines represents an attractive alternative with the potential to offer DIVA compatibility
and increased safety, commonly not associated with live-attenuated and killed vaccines [19].
The EHDV genome is comprised of 10 linear gene segments, which encode 7 structural proteins of
the outer and inner virus capsids (VP1-7) and 4 nonstructural proteins (NS1-3/3a) [1,20]. Previously, it has
been demonstrated that subunit vaccines containing multiple capsid proteins of the orbiviruses BTV and
African horse sickness virus (AHSV) can be immunogenic and efficacious in vivo (reviewed in [21–23]).
Additionally, immunization with the outer capsid VP2 protein only, which contains the primary
antigenic determinants for host-neutralizing antibodies, has been shown to protect susceptible species
from experimental BTV and AHSV challenges [24,25]. To date, EHDV subunit vaccines that have been
tested for immunogenicity or efficacy in naturally susceptible species have not been described.
The primary objective of this study was to generate a safe and efficacious subunit vaccine for the
protection of WTD against EHD. To this end, recombinant VP2 (rVP2) proteins from EHDV-2 and
EHDV-6 were produced using a baculovirus expression system. Purified rVP2 proteins, formulated
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with adjuvant, were evaluated for immunogenicity in mice and cattle. Also, an immunogenicity
and efficacy study in WTD was performed using the EHDV-2 rVP2 vaccine candidate administered
twice prior to challenge with a pathogenic EHDV-2 strain. Clinical, immunological, and virological
parameters were evaluated for 14 days post challenge (dpc), including postmortem macroscopic and
microscopic examination.
2. Materials and Methods
2.1. Ethics Statement
All animal studies were carried out in accordance with guidelines set forth by the Animal Welfare
Act, The Guide for the Care and Use of Laboratory Animals, 8th edition and/or The Guide for the Care
and Use of Agricultural Animals in Research and Teaching, 3rd edition, as applicable for each species.
Approval and oversight was granted by the Kansas State University Institutional Biosafety (IBC) and
Animal Care and Use (IACUC) Committees. The experimental work described herein falls under KSU
IBC protocol #1108 (approved 04/06/2016), and IACUC protocols #3721 (approved 03/07/2016), #3846
(approved 02/15/2017), and #3999 (approved 11/20/2017).
2.2. Generation of EHDV Recombinant Proteins
Total nucleic acid was extracted from EHDV-2 (Alberta 1962, SV-124-Canada) and EHDV-6
(Indiana 2012, 12-38993). Viruses were obtained from the Arthropod-Borne Animal Diseases Research
Unit (ABADRU) and Southeastern Cooperative Wildlife Disease Study (SCWDS), and double-stranded
RNA was purified by lithium chloride differential precipitation as described previously [26]. Full-length
VP2 cDNA of serotype 2 was amplified using the SuperScript III one-step RT-PCR system (ThermoFisher
Scientific, Carlsbad, CA), cloned into the pGEM-T vector (Promega, WI), then subcloned into the
pENTR/D Topo vector (ThermoFisher). Full-length VP2 cDNA of serotype 6 was amplified using the
SuperScript IV reverse transcriptase (ThermoFisher), followed by Q5 high-fidelity DNA polymerase
amplification (NEB Inc., Ipswich, MA), and then cloned into the pENTR/D Topo vector. The insertion
and orientation of the respective genes in donor plasmids were confirmed by restriction enzyme analysis
of the PCR-amplified gene and DNA sequencing (GENEWIZ, South Plainfield, NJ). pENTR-VP2
plasmids were propagated by transforming into One Shot TOP10 chemically competent E. coli, following
purification using the Qiagen Midiprep kit (Qiagen, Valencia, CA), then incubated with Baculo-Direct
linearized baculovirus DNA (ThermoFisher) containing Histidine Tag and LR clonase II to generate
the recombinant baculovirus DNA. The recombinant baculovirus DNA was transfected into Spodoptera
frugiperda 9 (Sf 9) cells using Cellfectin II reagent (ThermoFisher). Plasmid-transfected Sf9 cells
were cultured in SF900II medium (ThermoFisher) with 100 µM of ganciclovir to select recombinant
baculoviruses, and expression of recombinant proteins was confirmed via Western blot of infected Sf9
cell lysates using an anti-His (C-term)-horseradish peroxidase (HRP) monoclonal antibody (Figure 1)
and polyclonal anti-EHDV sera from deer. After confirmation of expression, recombinant proteins
with histidine tags were purified via affinity chromatography using Ni-NTA superflow resin (Qiagen)
after lysis of cells under native conditions. Cell pellets were resuspended in 50 mM sodium phosphate,
500 mM sodium chloride, 10 mM imidazole, 10% glycerol, and 400 units benzonase nuclease per
1 gram of pellet, at pH 8.0, and followed by twice freezing and thawing and 6 times short (10 sec)
sonication. The lysate was centrifuged at 10,000 rpm, at 4 ◦C for 20 min, and the supernatant was
used for Ni-NTA resin purification. Purified proteins were dialyzed against phosphate-buffered saline
(PBS; pH 7.4, 150mM NaCl, 4mM EDTA, 10% glycerol). Purification of EHDV proteins was confirmed
with Coomassie blue staining of SDS-PAGE gels and EHDV- or HisTag-specific antibodies in Western
blots. Protein concentrations were determined using the bicinchoninic acid (BCA) or Braford assay
(ThermoFisher) at an absorbance of 562 nm, using bovine serum albumin (Sigma-Aldrich) as the
protein standard. Protein aliquots were stored at −80 ◦C until use.
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2.3. Animals and Experimental Design
2.3.1. Mice
Immunogenicity of the EHDV rVP2 proteins was tested in two studies utilizing mice. For both
experiments, female CD1-ISG mice aged 6 weeks from Charles River Laboratories were randomized
into groups of five. Study 1: Mice were immunized subcutaneously (SC) on day 0 with 20 µg of purified
EHDV-2 rVP2 formulated with 25% volume of Montanide ISA25 adjuvant (Seppic, France) in a total
volume of 200 µL. Sham-vaccinated c ntrols rec ived pl cebo (1x PBS in adjuvant) SC. A third group
was immun zed SC with 105 TCID50 formaldehyde-inactivated EHDV-2 with adjuvant. Day 21 after
first vaccination, identical booster SC vaccinations were administered. Saphenous blood was collected
on 0, 21, and 35 days post vaccination (dpv), and mice were euthanized on 35 dpv. Study 2: Mice were
immunized SC on day 0 with 20µg of purified EHDV-6 rVP2 formulated with 25% volume of Montanide
ISA25 adjuvant (Seppic, France) in a total volume of 200 µL. Sham vaccinated mice received placebo
(1x PBS in adjuvant) SC. A third group was immunized SC with 105 TCID50 formaldehyde-inactivated
EHDV-6 with adjuvant. Booster vaccinations were administered, and samples were collected as in
Study 1. Saphenous blood was collected on days 0 and 35, and the mice were euthanized on 35 dpv.
In both studies, serum samples were tested for the presence of EHDV2- or EHDV6-neutralizing
antibodies as described in Section 2.5.
2.3.2. Cattle
Nine male Holstein calves aged approximately 3-4 months (average body weight: 102.2 kg)
were verified as serologically negative against EHDV by virus neutralization assay and randomized
into groups of 3. Each group received 150 µg purified rVP2 of EHDV-2 or EHDV-6 mixed with
Montanide ISA25 adjuvant (Seppic, France), or PBS with adjuvant (sham-vaccinated control group) in
2 mL. Injections were administered subcutaneously twice with an interval of 3 weeks (days 0 and 21).
Blood was collected via the jugular vein on 0, 21, and 35 dpv, and cattle were euthanized on 35 dpv.
Serum samples were tested for the presence of neutralizing antibodies for EHDV-2 and EHDV-6 as
described in Section 2.5.
2.3.3. White-Tailed Deer (WTD)
Six 5-month-old male WTD, captive-bred at the United States Department of Agriculture-
Agricultural Research Service (USDA-ARS), National Animal Disease Center (NADC) [27],
were randomized into 2 groups (n = 3; see Table S1) and received 150 µg purified EHDV-2 rVP2 with
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Montanide ISA25 adjuvant (Seppic, France), or PBS with adjuvant (sham group) in a total volume of 2
mL at NADC. Deer were verified as serologically negative against EHDV-1, -2, and -6 at the time of
vaccination by virus neutralization assays. Injections were administered SC twice with an interval
of 2 weeks (0 and 14 dpv). On 22 dpv, WTD were moved from NADC to a BSL-2 facility at Kansas
State University and allowed to acclimatize for eight days. Animals were housed in purpose-designed
deer pens to reduce stress. At 30 dpv, all animals were challenged with 106.74 pfu EHDV-2 in 2 mL
total volume administered via SC and intradermal injections (0.1–0.5 mL per injection) in the lateral
cervical and inguinal regions. Post-challenge, animals were monitored twice daily for general health
and clinical signs of EHDV infection, including decreased activity, skin erythema, hyperemia of oral
and ocular mucosa, lameness, tachypnea, and edema. Qualitative EHD clinical signs were observed
by two people independently. Prior to measuring rectal temperatures and collecting blood samples,
animals were sedated with xylazine (0.75–3 mg/kg; AnaSed, Lloyd Laboratories, IA, USA). Reversal of
sedation was performed using a slow intravenous administration of yohimbine (0.1–0.2 mg/kg; Lloyd
Laboratories). Blood was collected into serum and EDTA tubes on 0, 4, 6, 8, 12, and 14 d post challenge
(dpc). Anti-coagulated blood was analyzed for complete blood cell counts (CBCs), the presence of
infectious virus by virus isolation, and presence of viral RNA using RT-qPCR. Automated CBCs were
determined using a large animal CBC program on an ADVIA 2120 (Siemens, Malvern, PA), followed by
manual differential count (Kansas State Veterinary Diagnostic Laboratory, KSVDL). Electronic platelet
quantitation was returned as “invalid” for multiple samples and thus not reported. Neutralizing
antibodies in sera were detected and quantitated using virus neutralizing tests (see 2.5 below), and
serum total protein concentration was determined using a hand-held refractometer (TekoPlus, Kowloon,
Hong Kong). On 14 dpc, animals were sedated and subsequently euthanized using an overdose of
intravenous sodium pentobarbital (minimum of 85–100 mg/kg; Fatal Plus, Vortech Pharmaceuticals,
Ltd., MI, USA) with intracardiac administration of additional pentobarbital as needed in accordance
with the AVMA Guidelines for the Euthanasia of Animals (2013 Edition).
2.3.4. Postmortem Examination and Analysis
After humane euthanasia, postmortem gross pathology examination was performed and tissues
were sampled. Tissue samples for histological analysis were fixed in 10% buffered formalin for a
minimum of 10 days prior to trimming and paraffin embedding. Fresh tissues (lung, liver, spleen,
and kidney) were collected and were stored at −80 ◦C until processed. Following standard embedding
in paraffin and the preparation of Hematoxylin and Eosin (H&E) stained slides, histopathology
was performed independently by two pathologists. Tissues evaluated histologically included the
heart, aorta and main pulmonary artery, lung, liver, kidney, spleen, pancreas, intestinal tract, urinary
bladder, skeletal muscle and bone marrow, thymus and the prescapular, tracheobronchial, thoracic,
gastrohepatic, mesenteric, and renal lymph nodes.
2.4. Viruses
EHDV-2 Alberta (SV-124-Canada 1962; ABADRU’s virus collection) and EHDV-6 Indiana
(12-38993; provided by SCWDS) were used for VP2 cloning and virus neutralization tests. EHDV-2
strain cc12-304, prepared from the spleen of an infected white-tailed deer from Kansas in 2012 [28],
was kindly provided by Mark Ruder, SCWDS, propagated in a Culicoides sonorensis cell line (CuVa W8
cells), and used for the WTD challenge [29].
2.5. Virus Neutralization Assay
Virus neutralization assays were performed based on Office International des Epizooties
(OIE-World Organization for Animal Health) and USDA protocols [18] using EHDV-2 (Alberta 1962)
and EHDV-6 (Indiana 2012). In brief, sera from immunized animals (mice, cattle, and deer) were
inactivated at 56 ◦C for 30 min, then initially diluted 10-fold in MEM with 0.5% FBS (Atlantic Biologicals,
Flowery Branch, GA) and 1x antibiotic-antimycotic (Fisher Scientific, Palatine, IL), and then 2-fold
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50 µL dilutions from 1/10 to up to 1/10,240 were made in 96-well culture plates in quadruplicate. Virus
with 100 TCID50 in 50 µL was added into each well, and plates were incubated for 1 h at 37 ◦C. Vero
cells with 2 × 104 cell per well in 100 µL of MEM with 5% FBS (Atlantic Biologicals, Flowery Branch,
GA) and 1x antibiotic-antimycotic (Fisher Scientific, Palatine, IL) were added and then incubated for
5 d at 37 ◦C with 5% CO2. Wells were scored for the degree of cytopathic effects (CPE). The neutralizing
antibody titer was calculated and recorded as the reciprocal of the highest serum dilution capable of
preventing CPE in the respective cell culture wells.
2.6. Virus Detection
2.6.1. Real-time Quantitative PCR
RT-qPCR specific for the S10 gene of EHDV serotype2 [30] was modified and performed as
one-step quantitative reverse transcription real time PCR (RT-qPCR) using RNA purified from whole
EDTA blood or tissue homogenates. For blood, an equal volume (250 µL) of whole blood and Qiagen
RLT buffer were combined and subjected to heat (70 ◦C) for 5 min in a Vortemp (ISC Bioexpress,
Kaysville, Utah) prior to extraction. Tissue lysates were made by processing 0.4 g of minced tissue
into 1.5 mL of ATL buffer with one 5 mm stainless steel bead on a tissue homogenizer (Qiagen Tissue
Lyser) using 3 rounds of 30 s bursts at 30 MHz. A 40 µL volume of protease K (Qiagen) was added,
and samples were vortexed and held at room temperature overnight. A 150 µL volume of clarified
lysate was mixed with 150 µL of RLT buffer and heated at 70 ◦C for 5 min. A 250 µL aliquot of blood
lysate plus 150 µL of sterile PBS (400 µL total), or 300 µL of the RLT tissue lysate, was processed
using a magnetic bead processor (Biosprint, Qiagen, Hilden, Germany) using a commercially available
magnetic bead total nucleic extraction kit (GeneReach Biotechnology Corp, Lexington, MA, USA) as
per the manufacturer’s recommendation with modifications; isopropyl alcohol replaced ethanol in the
bead binding step, the fourth wash consisted of 100% molecular grade ethanol, and nucleic acids were
eluted in 70 µL of elution buffer.
RT-qPCR was performed using a 20 µL reaction and 5 µL of purified RNA, Quanta qScript
XLT 1-step RT-qPCR Toughmix, nuclease-free water, and 0.4 µm primers and 0.1 µm probe on
a CFX 96 RT-qPCR machine (BioRad, Hercules, California). The EHDV serotype 2 primer and
probe set was identical to that previously published in Wilson et al. 2009 [30]: forward primer
GCGTTGGATATATTGGACAAAGC, reverse primer GCATACGAAGCATAAGCAACCTT, and FAM
probe TCAAATCAAACGGGCGCAACTATGG. Thermocycling conditions consisted of 50 ◦C reverse
transcriptase step for 20 min, then a 5 min hold at 95 ◦C followed by 45 cycles of 95 ◦C for 10 s and 60 ◦C
for 1 min. Samples were tested in triplicate with mean cycle threshold (Ct) used for gene copy number
determination. Negative and positive (in vitro transcribed RNA [IVT RNA], see below) extraction and PCR
controls were utilized for standard curve generation for the EHDV S10 gene copy number determination.
For RT-qPCR, EHDV IVT RNA was generated using the MEGAscript T7 transcription kit
(ThermoFisher) using a plasmid containing a PCR-generated EHDV S10-specific amplicon as well as
lyophilized PCR enzyme mix (GeneReach Biotechnology Corp, USA) and T7 promoter and terminator
primers (Integrated DNA Technologies, Coralville, IA, USA). The EHDV plasmid (pBluescript II
SK(-), synthesized by GenScript, Piscataway, NJ, USA), contained 410 base pairs of the EHDV
S10 segment of the serotype 1 strain New Jersey Epizootic hemorrhagic disease virus (GenBank
AM744986.1), which aligns 100% with serotype 2 strain 439 (Genbank AM744996.1). IVT RNA was
DNase treated 3 times, column purified (MEGAclear, ThermoFisher, Waltham, MA, USA), checked
for contaminating DNA with paired RT-qPCR/qPCR, and quantitated with Qubit XR and the Qubit
Fluorometer (Thermofisher). EHDV gene copy number was calculated using http://www.endmemo.
com/bio/dnacopynum.php. Ten-fold serial dilutions of IVT stock RNA (109–10−1 copies/reaction) were
utilized to generate a six-point standard curve using nine PCR well replicates per dilution. Copy
number (CN) of the S10 gene for respective samples were mathematically determined using reference
standard curve methodology, mean Ct, and the slope and intercept of the S10 gene IVT RNA standard
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curve. Data are reported as PCR-determined copy number/mL for blood and per reaction for tissues,
which equates to approximately 2.8 mg of tissue total nucleic acid. Calculated copy numbers less than
150 (equivalent to Ct greater than 36) were considered beyond the limits of detection for this assay.
2.6.2. Virus Plaque Assay
Virus challenge material and WTD whole blood were titrated by plaque assay on Vero MARU cells
(RRID:CVCL_EJ70). Confluent cell monolayers in 6-well tissue culture plates were inoculated with
ten-fold serially diluted samples in 199E medium (Sigma-Aldrich, St. Louis, MO, USA), supplemented
with 2% FBS and 1x penicillin/streptomycin/fungizone (PSF) (Atlanta Biologicals, Flowery Branch, GA,
USA) and incubated for 1 h at 37 ◦C, 5% CO2 with rocking every 15 min. Following adsorption, the
inocula were removed, and 3 mL of a 1:1 mixture of 2% carboxymethyl cellulose (Sigma-Aldrich) in 2x
199E medium (5% FBS, 2x PSF) was added. Plates were incubated at 37 ◦C, 5% CO2 for 10-14 days.
Cells were fixed and stained with crystal violet fixative (25% formaldehyde, 10% ethanol, 5% acetic
acid, 1% crystal violet). Virus titers were calculated from visible plaques.
2.7. Statistical Analyses
Statistical significance of differences between two groups was determined using a two-tailed
Student’s t-test in Prism 7 (GraphPad Software, San Diego, CA); p < 0.05 was considered significant.
3. Results
3.1. Neutralizing Antibody Responses in Vaccinated Mice
To first investigate the ability of the recombinant VP2 proteins to induce neutralizing immune
responses in vivo, mice were immunized with either EHDV-2 rVP2, EHDV-6 rVP2, an inactivated
homologous virus, or adjuvant control (n = 5/group) at days 0 and 21. Terminal sera at 35 dpv
were tested for neutralizing antibodies (Table 1). By 35 dpv, mice immunized with EHDV-2 rVP2
developed antibodies capable of neutralizing homologous virus with titers between 1:40 and 1:80.
Mice immunized with EHDV-6 rVP2 had titers between 1:800 and 1:3200 against EHDV-6. No
neutralizing antibodies were detected in animals vaccinated with an adjuvant control, inactivated
EHDV-2, or inactivated EHDV-6.




Adjuvant Control Inactivated EHDV-2 EHDV-2 rVP2
0 dpv - - -
35 dpv - - 53.33 ± 19.3
Study 2
Vaccine Group
Adjuvant Control Inactivated EHDV-6 EHDV-6 rVP2
0 dpv - - -
35 dpv - - 1800 ± 1006
Sera from vaccinated mice were collected at 35 days post vaccination (dpv), diluted 1:10 to 1:3200, and tested for
the ability to neutralize EHDV-2 (Study 1, top) or EHDV-6 (Study 2, bottom) in separate studies. Reported titers
represent the reciprocal of the highest serum dilution capable of reducing cytopathic effects (CPE) more than 75%.
“-” indicates neutralization was not observed at the lowest dilution; groups contain n = 5 mice except EHDV-6 rVP2,
which contained n = 4 following the loss of one mouse prior to 35 dpv.
3.2. Neutralizing Antibody Responses in Vaccinated Cattle
The recombinant EHDV-2 and EHDV-6 VP2 proteins were next tested for immunogenicity in
cattle. Calves were immunized with EHDV-2 rVP2, EHDV-6 rVP2, or adjuvant control on days 0 and
21 (n = 3/group). Serum antibody levels were measured by a virus neutralization assay (Table 2) on
0 dpv (prior to immunization), 21 dpv (after a single immunization), and 35 dpv (study end). One
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out of three calves immunized with EHDV-2 rVP2 developed a neutralizing titer of 1:30 by 21 dpv.
By 35 dpv, the three EHDV-2 rVP2-vaccinated calves had EHDV-2 neutralizing antibody titers between
1:360 and 1:1120. Of the three calves vaccinated with EHDV-6 rVP2, two developed neutralizing
antibody titers less than 1:20 by 21 dpv. By 35 dpv, neutralizing antibody titers in the three calves
immunized with EHDV-6 rVP2 were between 1:160 and 1:320. No neutralizing antibodies were
detected in animals vaccinated with the adjuvant alone. Cross-neutralization reactivity of EHDV-2 and
EHDV-6 hyperimmune sera at 35 dpv was at or below the assay detection limit.
Table 2. Neutralizing antibody responses in cattle vaccinated with EHDV rVP2 proteins.
Vaccine Group α-EHDV-2 Titers α-EHDV-6 Titers
0 dpv 21 dpv 35 dpv 0 dpv 21 dpv 35 dpv
Adjuvant Control - - - - - -
EHDV-2 rVP2 - 10 ± 16.0 706.7 ± 384 - - 5.8 ± 5.2
EHDV-6 rVP2 - - 4.2 ± 7.0 - 5.8 ± 8.0 226.7 ± 83
The reported titers represent the reciprocal of the mean highest serum dilution capable of reducing CPE more than
75%; n = 3 for each group; “-” indicates neutralization was not observed at the lowest serum dilution.
3.3. Neutralizing Antibody Responses in Vaccinated and EHDV-Challenged WTD
To evaluate the efficacy of vaccine candidates in the species most susceptible to EHDV
infection, the EHDV-2 rVP2 formulation, which showed a good response in cattle, was selected
for a challenge study in WTD. Five-month-old captive-bred WTD were vaccinated with EHDV-2
rVP2 or sham-vaccinated with adjuvant control at 0 and 14 dpv (n = 3/group). At 30 dpv, all animals
were challenged with 6.74 log10 pfu EHDV-2 (Kansas 2012). At the time of challenge (30 dpv/0 dpc),
the sham-vaccinated animals had no detectable antibodies to EHDV-2 (Figure 2). Neutralizing titers of
1:10 were first detected on 6 dpc in two of the three sham-vaccinated deer and reached a maximum
of 1:2560 to ≥ 1:5120 by 14 dpc. Titers in the EHDV-2 rVP2-vaccinated animals ranged from 1:240 to
1:320 prior to challenge (30 dpv/0 dpc). By 4 dpc, titers had increased to 1:320 to 1:2560, indicating an
anamnestic response. Vaccinee titers reached a maximum of 1:2560 to ≥ 1:5120 by 14 dpc.
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sham-vaccinated WTD (filled shapes, solid lines) and EHDV-2 rVP2-vaccinated WTD (open shapes, 
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Figure 2. Neutralizing antibodies of white-tailed deer (WTD) challenged with EHDV-2. Sera from
sham-vaccinated WTD (filled shapes, solid lines) and EHDV-2 rVP2-vaccinated WTD (open shapes,
dashed lines) were collected at 0, 4, 6, 8, 12, and 14 dpc and tested for the ability to neutralize EHDV-2.
Reported titers represent the reciprocal of the highest serum dilution capable of reducing cytopathic
effects (CPE) more than 75%. The lowest assay dilution was 1:10; therefore, values on the x-axis (y = 1)
represent titers <10. Legend indicates individual animal identification numbers.
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3.4. Clinical Parameters in EHDV-2 Challenged WTD
Following challenge with EHDV-2, all sham-vaccinated deer and two out of three rVP2-vaccinated
deer had body temperatures exceeding the baseline mean of 39.2 + 0.20 ◦C on at least one day (Figure 3A).
All three sham-vaccinated deer, but no rVP2-vaccinated deer, developed body temperatures exceeding
40 ◦C. On 6 dpc, the mean rectal temperature of the sham-vaccinated group (40.2 ± 0.20 ◦C) was
significantly higher than the mean rectal temperature of vaccinated deer (39.3 + 0.10 ◦C). Beginning at 6
to 8 dpc, facial edema and increased recumbency were observed with all three sham-vaccinated animals.
The most severe clinical signs were observed in animal #1764, which also developed hyperemia of the
oral and ocular mucosa. EHD-related clinical signs were not observed in the WTD vaccinated with
rVP2 during the study.
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Figure 3. Body temperatures and peripheral lymphocyte numbers in WTD following challenge with
EHDV-2. (A) Rectal temperatures as measured in sham-vaccinated WTD (closed shapes, solid lines)
and EHDV-2 rVP2-vaccinated WTD (open shapes, dashed lines) on 0, 4, 6, 8, 12, and 14 dpc. Horizontal
dotted line indicates group mean baseline temperature. Asterisk indicates p = 0.013. (B) Lymphocyte
counts performed on peripheral blood samples collected from all animals at 0, 4, 6, 8, 12, and 14 dpc,
excepting #1756 on 0 dpc due to the sample clotting prior to analysis. Lines on vertical bars indicate
minimum, maximum, and mean absolute lymphocyte counts for the sham-vaccinated group (grey bars)
and rVP2-vaccinated group (white bars) on each sample day. Horizontal dotted lines indicate the 95%
confidence interval of the group baseline mean absolute lymphocyte count at 0 dpc. Asterisks indicate
p = 0.017 (6 dpc) and p = 0.032 (8 dpc).
Peripheral lymphocyte counts were significantly lower in the sham-vaccinated deer compared to
the rVP2-vaccinated deer on 6 dpc (Figure 3B; 733 + 153 cells/µL, sham; 1600 + 346 cells/ µL, rVP2) and
8 dpc (900 + 360 cells/µL, sham; 1600 + 100 cells/µL, rVP2). Severe lymphopenia, characterized by
absolute lymphocyte counts less than 1000 cells/µL, has previously been associated with severe EHD
and death in WTD challenged with EHDV-2 [31]. All sham-vaccinated animals exhibited lymphocyte
counts below 1000 cells/µL on at least one day, and in one animal (#1764), on four sampling days
(4-12 dpi). Lymphocyte counts did not drop below 1000 cells/µL in any of the rVP2-vaccinated animals
on any day. No changes were detected in the serum or plasma protein levels of the rVP2-vaccinated
and sham-vaccinated animals (data not shown).
3.5. Blood Viral RNA Loads and Viremia in Vaccinated/Challenged WTD
Using RT-qPCR, EHDV-specific RNA was detected in the peripheral blood of all sham-vaccinated
animals following challenge, with the peak RNAemia levels ranging from 6.33 to 9.15 log10 genome
copies/mL on 6 dpc (Figure 4). Viral RNA was not detected in the blood of rVP2-vaccinated animals
at any time point post infection. EHDV was isolated from the blood of one sham-vaccinated animal,
#1764, which also had the highest levels of viral RNA in whole blood. Blood virus titers in this animal
were 4.0 log10 pfu/mL on day 6 and 3.85 log10 pfu/mL on day 8, as measured by plaque assay.
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Figure 4. EHDV-2 RNA detected in peripheral blood of rVP2-vaccinated WTD challenged with EHDV-2.
EDTA whole blood was collected from animals at 0, 4, 6, 8, 12, and 14 dpc, and EHDV RNA was
quantified using the standard curve method and specific RT-qPCR for the detection of the S10 gene of
EHDV-2 [30]. Closed shapes, sham-vaccinated WTD; open shapes, rVP2-vaccinated WTD.
3.6. Postmortem Analyses and Detection of Viral RNA in Tissues
At necropsy on 14 dpc, all WTD exhibited variable pulmonary congestion and edema.
Because EHDV infection, as well as handling stress, euthanasia drugs, and cardiac arr st can
pulmonary congestion and edema, it was not possible to determine the relevance of these l sions in this
study. Otherwis , no rVP2-vaccinated WTD exhibited gross and histopathological lesio s attrib ted
to EHDV infection, and no viral RNA was detected in the tis ues collected from rVP2-vaccinated
deer (Tabl 3). Gross and histopathological l sio s in the three sham-vaccinated animals (#1756,
#1760, #1764) were consistent with EHDV infection and characterized by necrotizing vasculitis and
hemorrhagic lesions in multiple organs (Figure 5). Viral RNA was detected in two or more tissue of all
sham-vaccinat d, EHDV-infected deer. WTD #1764, which had the highest blood viremia as measured
by RT-qPCR and plaque assay, also ha the highest amount of viral RNA detected in various tissue
collected at necropsy.
Table 3. EHDV-2 RT-qPCR in various white-tailed deer tissues.
Tissue Sham-Vaccinated WTD rVP2-Vaccinated WTD
#1756 #1760 #1764 #1755 #1763 #1766
Lung 3.37 2.72 5. 5 ND ND ND
Spleen ND 2.63 3.78 ND ND ND
Liver ND 3.18 (S) 3.19 ND ND ND
Kidney 2.53 3.43 ND ND ND ND
Tissues were collected at necropsy on 14 dpc, and EHDV-2 RNA was quantified using the standard curve method
and specific RT-qPCR for the detection of the S10 gene of EHDV -2. Values are reported as log10 copies of EHDV-2
RNA/reaction; “ND” = not detected; “(S)” = suspect: sample was positive in only one of 3 replicates.
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i i t l ical lesions consi tent with EHDV in sham-vaccinated WTD. (A) #1756; cerebral cortex;
lymphoplasmacytic en ephalitis with vasculitis and periv sculitis of the small vessel and large vessels
( rows) accomp nied by gliosis (small thin arrow) (2X). (B) #1760; liver; lymphoplasmacytic vasculitis
(arrow on vessel lumen) and portal/periportal hepatitis (20X). (C) #1756; lung; lymphoplasmacytic
vasculitis and perivasculitis, medium to large veins (5X) (D) #1760; kidney; lymphoplasmacytic vasculitis
(arrows) with hemorrhage (arrowheads) (40X). (E) #1764; heart; extensive multifocal myocardial necrosis
and hemorrhage (*) in the papillary muscle with hemorrhage and edema of the endocardium (arrowhead)
(5X). (F) #1764; aorta; centralized necrosis of the tunica media with loss of cellular detail (*) bordered by
multifocal he orrhage (arrowhead) (5X).
4. Discussion
Recombinant protein vaccines have inherent advantages amongst potential EHDV vaccine
strategies. Unlike live-attenuated EHDV vaccines, which have the potential to reassort their
gene segments with those of wild-type (field) strains [32], subunit vaccines have minimal risk
of environmental impact. Because they are comprised of a limited number of selected antigens, they can
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also be purpose-designed with DIVA compatibility in mind, unlike live-attenuated or most inactivated
virus vaccines. Specifically, immunization of animals with VP2 alone should not induce antibodies
to the EHDV core protein VP7; the highly immunogenic EHDV VP7 protein is the basis of currently
available EHD group-specific serological diagnostic tests for the diagnosis of EHDV infection in wild
and domestic animals [33,34]. The evaluation of DIVA compatibility of the VP2 subunit vaccine is
beyond the scope of this vaccine efficacy study and will be investigated in subsequent studies.
Historically, recombinant subunit vaccine candidates have demonstrated efficacy in target host
species for similar viruses such as BTV and AHSV [25,35]. Virus-like particles comprised of multiple
EHDV capsid proteins have demonstrated the ability to induce neutralizing antibodies in rabbits [36].
Here, we provide evidence that a subunit formulation using recombinant EHDV serotype 2 VP2 is
sufficient to protect WTD from experimental EHDV challenge with a homologous serotype virus.
The VP2 protein of EHDV, like that of BTV, is the outermost capsid protein and contains the
primary antigenic determinants for host-neutralizing antibodies [37,38]. In this study, we confirmed
that a formulation using baculovirus-expressed rVP2 can induce neutralizing antibody responses
in vivo in three different animal species and was protective in WTD after virulent EHDV challenge.
The fact that neutralizing antibodies were not detected in mice vaccinated with inactivated EHDV-2 or
inactivated EHDV-6 most likely was due to the virus dose used for vaccination not being high enough
for inducing detectable neutralizing antibodies.
The duration of protective immunity by EHDV-2 rVP2 is not yet known and requires future
investigation, which should include determination of optimal vaccination intervals and formulation
for potential use in the field. Additionally, dose response studies would be useful to optimize relative
potency of the rVP2 antigens. The cattle studies described herein indicate that the neutralizing
antibodies generated by rVP2 proteins may be serotype specific (i.e., no significant cross-neutralization
reactivity between EHDV serotypes was observed). This is not unexpected, as VP2 is the primary
determinant of serotype specificity. However, with three EHDV serotypes circulating in North
America and shifting epidemiological dynamics, protection from multiple serotypes would be
desirable. Having demonstrated that selected rVP2 proteins are immunogenic in a monovalent
vaccine formulation, efforts are currently underway to test bi- and multivalent vaccine formulations
that contain rVP2 proteins from two or more serotypes to address the need for broader protection.
Detailed determination of the VP2-neutralizing epitopes would also facilitate development of
multi-epitope formulations.
The clinical presentation of EHD is often highly variable in both natural and experimental
infections. Some infections are subclinical, while others are chronic or insidious, and others are
acutely lethal. In this study, the control sham-vaccinated EHDV-infected deer presented with signs
ranging from moderate to severe, with one animal (#1764) exhibiting clear clinical and pathologic
evidence of classic fulminant EHD. The variability observed in body temperatures during the study
was not unexpected for a non-domesticated species; some temperature elevations observed during
the study likely were attributable to the increase in activity during deer handling prior to measuring
temperatures. The gross, histological, and clinical evidence of EHD in the sham-vaccinated group was
not observed in the VP2-vaccinated group, both challenged with EHDV. Although all WTD exhibited
variable pulmonary congestion and edema, its presence in both animal groups suggests this finding
likely could be attributed to handling and/or barbiturate euthanasia. The absence of detectable viral
RNA in the peripheral blood or tissues of the rVP2 vaccinees demonstrated that these animals were
protected from infection following EHDV challenge. The prevention of viremia is not only relevant for
protection from clinical disease, but it also addresses the need to interrupt midge transmission to naïve
hosts, as deer with lower titers of viremia are less infectious to Culicoides vectors than are animals with
high titers [5,39].
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5. Conclusions
An experimental vaccine using baculovirus-expressed EHDV-2 rVP2 effectively induced
neutralizing antibodies in two EHDV target species and mice, and provided sterilizing immunity
following challenge with a homologous virulent virus in the primary target host species, WTD. Mice and
cattle vaccinated with baculovirus-expressed EHDV-6 rVP2 produced homologous virus-neutralizing
antibodies. The presented results indicate that a baculovirus-based EHDV VP2 vaccine could be an
effective tool in preventing clinical EHD and reducing virus transmission via arthropod vectors by
reducing viremia in WTD. A recombinant subunit protein-based vaccine such as this would also offer
the potential for DIVA compatibility and wider safety margins than live-attenuated vaccines. The VP2
protein subunit approach investigated here, therefore, represents a promising strategy to fill an unmet
need for a safe and efficacious countermeasure for EHDV.
Supplementary Materials: The following is available online at http://www.mdpi.com/2076-393X/8/1/59/s1,
Table S1: WTD used for the vaccine efficacy study.
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